$10.59
+0.09
(+0.86%)▲
11.71%
Downside
Day's Volatility :11.78%
Upside
0.08%
93.86%
Downside
52 Weeks Volatility :94.72%
Upside
13.9%
Period | Calamp Corp. | Sector (Technology) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.21% | 15.3% | 0.0% |
6 Months | 170.33% | 15.4% | 0.0% |
1 Year | 49.54% | 32.1% | 0.0% |
3 Years | -95.56% | 44.1% | -26.0% |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
What analysts predicted
Downside of 83.29%
FY21 | Y/Y Change | |
---|---|---|
Revenue | 295.8M | ↓ 4.13% |
Net Income | -31.1M | ↑ 47.22% |
Net Profit Margin | -10.53% | ↓ 3.67% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 294.9M | ↓ 0.3% |
Net Income | -32.5M | ↑ 4.31% |
Net Profit Margin | -11.02% | ↓ 0.49% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 294.9M | ↓ 0.3% |
Net Income | -32.5M | ↑ 4.31% |
Net Profit Margin | -11.02% | ↓ 0.49% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 186.2M | ↓ 36.86% |
Net Income | -93.3M | ↑ 187.05% |
Net Profit Margin | -50.08% | ↓ 39.06% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 186.2M | ↓ 36.86% |
Net Income | -93.3M | ↑ 187.05% |
Net Profit Margin | -50.08% | ↓ 39.06% |
FY24 | Y/Y Change | |
---|---|---|
Revenue | 186.2M | ↑ 0.0% |
Net Income | -93.3M | ↑ 0.0% |
Net Profit Margin | -50.08% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 70.9M | ↑ 0.0% |
Net Income | -4.0M | ↑ 0.0% |
Net Profit Margin | -5.69% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 70.9M | ↑ 0.0% |
Net Income | -4.0M | ↑ 0.0% |
Net Profit Margin | -5.69% | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 61.7M | ↑ 0.0% |
Net Income | -4.2M | ↑ 0.0% |
Net Profit Margin | -6.85% | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 61.7M | ↑ 0.0% |
Net Income | -4.2M | ↑ 0.0% |
Net Profit Margin | -6.85% | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 53.6M | ↑ 0.0% |
Net Income | -85.0M | ↑ 0.0% |
Net Profit Margin | -158.52% | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 53.6M | ↑ 0.0% |
Net Income | -85.0M | ↑ 0.0% |
Net Profit Margin | -158.52% | ↑ 0.0% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 391.6M | ↓ 9.73% |
Total Liabilities | 316.2M | ↓ 6.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 380.1M | ↓ 2.93% |
Total Liabilities | 365.8M | ↑ 15.7% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 380.1M | ↓ 2.93% |
Total Liabilities | 365.8M | ↑ 15.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 380.1M | ↑ 0.0% |
Total Liabilities | 365.8M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 372.2M | ↑ 0.0% |
Total Liabilities | 359.8M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 372.2M | ↑ 0.0% |
Total Liabilities | 359.8M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 363.9M | ↑ 0.0% |
Total Liabilities | 353.4M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 363.9M | ↑ 0.0% |
Total Liabilities | 353.4M | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 281.2M | ↑ 0.0% |
Total Liabilities | 355.4M | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 281.2M | ↑ 0.0% |
Total Liabilities | 355.4M | ↑ 0.0% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.6M | ↑ 0.0% |
Investing Cash Flow | -13.7M | - |
Financing Cash Flow | -27.3M | ↑ 0.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.2M | ↑ 0.0% |
Investing Cash Flow | -7.6M | - |
Financing Cash Flow | -2.6M | ↑ 0.0% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.9M | ↑ 0.0% |
Investing Cash Flow | -11.1M | - |
Financing Cash Flow | -909.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.0M | ↑ 173.14% |
Investing Cash Flow | -2.0M | - |
Financing Cash Flow | -257.0K | ↓ 197.35% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.1M | ↓ 339.7% |
Investing Cash Flow | -1.9M | - |
Financing Cash Flow | -114.0K | ↓ 55.64% |
Sell
Neutral
Buy
Calamp Corp. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Calamp Corp. | -1.21% | 170.33% | 49.54% | -95.56% | -95.66% |
Regeneron Pharmaceuticals, Inc. | -17.08% | -14.93% | 3.69% | 33.14% | 140.62% |
Biontech Se | -6.53% | 20.69% | 11.13% | -53.0% | 460.49% |
Alnylam Pharmaceuticals, Inc. | -0.43% | 84.38% | 71.37% | 57.41% | 200.09% |
Vertex Pharmaceuticals Incorporated | 8.52% | 22.22% | 38.3% | 174.99% | 155.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Calamp Corp. | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Regeneron Pharmaceuticals, Inc. | 20.41 | 20.41 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.1 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Calamp Corp. | Sell | $660.3K | -95.66% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 140.62% | 20.41 | 33.61% |
Biontech Se | Buy | $25.9B | 460.49% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.1B | 200.09% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 155.94% | 32.84 | -4.51% |
Insights on Calamp Corp.
Revenue is down for the last 9 quarters, 78.88M → 53.62M (in $), with an average decrease of 4.5% per quarter
Netprofit is down for the last 5 quarters, -4.03M → -85.00M (in $), with an average decrease of 479.2% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.4% return, outperforming this stock by 21.9%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.4% return, outperforming this stock by 153.0%
West Paces Advisors Inc
calamp (nasdaq: camp) is leading the internet of things revolution with its extensive portfolio of intelligent communications devices, robust and capable cloud platform, and targeted software applications. calamp enables customers to optimize operations by collecting, monitoring and efficiently reporting business-critical data and desired intelligence from high-value remote assets. with a heritage in the m2m market, calamp has more than five million devices connected to its iot cloud. partners across transportation, oil and gas, and public safety markets leverage calamp to effectively gather mission- and business-critical data to make intelligent, actionable decisions. for more information, please visit www.calamp.com.
Organization | Calamp Corp. |
Employees | 58 |
CEO | Mr. Joshua Mandel-Brehm |
Industry | Telecommunications Equipment |
Cactus Acquisition Corp 1 Ltd
$10.59
+0.86%
Rigel Resource Acquisition Corp
$10.59
+0.86%
Fortune Rise Acquisition Corp
$10.59
+0.86%
Canada Goose Holdings Inc.
$10.59
+0.86%
J W Mays Inc
$10.59
+0.86%
American Shared Hospital Services
$10.59
+0.86%
Cambria Shareholder Yield Etf
$10.59
+0.86%
J-long Group Ltd.
$10.59
+0.86%
Cps Technologies Corp
$10.59
+0.86%